Initially focused on tobacco and industrial interests, the Group underwent a transformation in 2000, unbundling its tobacco assets and refocusing as Remgro Limited, a diversified investment holding company. Over the decades, it has evolved through prudent capital allocation and strategic partnerships into one of South Africa’s leading investment entities
Remgro's founding history goes back to the 1940s when the founder of the Group, Dr Anton Rupert, established the tobacco company Voorbrand, forerunner of Rembrandt Group Limited (Rembrandt), in Johannesburg, South Africa. Rembrandt was incorporated in 1948.
Rembrandt entered the South African cigarette and tobacco industry in 1948 and expanded overseas through international partnerships in the 1950s.
Rembrandt's interests in the wine and spirits industry also date back to the 1940s when Dr Rupert and Mr D W R Hertzog founded Distillers Corporation.
Rembrandt was listed on the Johannesburg Stock Exchange in 1956.
In 1972, the overseas tobacco interests of Rembrandt were consolidated in Rothmans International, which was listed on the London Stock Exchange.
Since the 1970s, Rembrandt expanded its interests outside tobacco, wine and spirits with investments in various other economic sectors in South Africa, among which were banking and financial services, mining, printing and packaging, medical services, engineering and food interests.
In 1988, the separation of local and overseas interests was affected by the founding of Compagnie Financière Richemont AG (Richemont) – a Swiss-listed luxury goods group that included brands such as Cartier, Dunhill and Mont Blanc which then acquired a share in Rothmans International.
During 1993, Rembrandt co-founded South Africa’s first cellular telephony company, Vodacom, which was eventually disposed of in 2006 by VenFin Limited (VenFin).
In 1995, Rembrandt and Richemont consolidated their respective tobacco interests in Rothmans International, at the time the world’s fourth largest cigarette manufacturer, which was then delisted.
In 1999, these interests were merged with those of British American Tobacco plc (BAT), the world’s second largest cigarette producer. Subsequent to this restructuring the investment in BAT has been held through a joint holding company in which Rembrandt (Remgro’s predecessor) and Richemont held 33⅓% and 66⅔% respectively. Following the above restructuring, Rembrandt became a pure investment holding company.
In September 2000, the restructuring of Rembrandt was advanced when the South African holding structure, consisting of four listed companies, was collapsed into two listed companies, namely Remgro and VenFin. Following this, Remgro represented Rembrandt's established tobacco, financial services, mining and industrial interests. The telecommunication and technology interests were housed in VenFin.
In January 2001, Remgro exchanged its 8.2% interest in Billiton plc and its 11.3% interest in Gold Fields Limited for a 9.3% interest in FirstRand Limited and a 23.1% interest in Rand Merchant Bank Holdings Limited.
In November 2008, Remgro unbundled its investment in BAT by way of an interim dividend in specie amounting to R55.2 billion. Following the BAT unbundling, the Group's remaining interests consisted mainly of investments in banking and financial services, printing and packaging, motor components, glass products, medical services, mining, petroleum products, food, wine and spirits, and various other trademark products.
In November 2009, Remgro and VenFin merged again, adding media and technology interests to the Group's investments.
In June 2015, Remgro facilitated Mediclinic International Limited's (Mediclinic) acquisition of a 29.9% stake in Spire Healthcare Group plc and participated in a Mediclinic rights issue. Mediclinic and Al Noor Hospitals Group plc combined in February 2016.
In October 2016, Remgro completed a rights issue for a total consideration of R9 945 million, to have cash resources and flexibility to capitalise on investment opportunities
In July 2018, Remgro disposed of its 25.75% shareholding in Unilever South Africa Proprietary Limited (Unilever) in exchange for Unilever's Spreads business in Southern Africa, now Siqalo Foods, for R7 000 million, and a cash consideration of R4 900 million.
In June 2020, Remgro unbundled its 28.2% investment in RMB Holdings Limited by way of an interim dividend in specie amounting to R23.9 billion.
In June 2023, Remgro and MSC Mediterranean Shipping Company SA acquired the entire issued ordinary share capital of Mediclinic, other than the Mediclinic shares Remgro already owned. Mediclinic shareholders received 501 pence per Mediclinic share. Remgro invested a further £221 million and increased its interest in Mediclinic from 44.6% to 50.0%.
In April 2023, the Heineken International B.V. Southern African business, including an interest in Namibia Breweries Limited, combined with the bulk of the Distell Group Holdings Limited (Distell) business (consisting of its cider, other RTDs and spirits and wine business) in Heineken Beverages Holdings Limited (Heineken Beverages). Remgro received a 15.5% interest in Heineken Beverages and has subsequently increased its investment to 18.8%. Distell simultaneously unbundled its subsidiary, Capevin Holdings Proprietary Limited (Capevin), which held Distell's remaining assets, including its Scotch whisky business, and Remgro received an economic interest of 31.4% in Capevin.
On 1 July 2024, Remgro received 714 057 943 Rainbow shares as part of RCL Foods’ formal separation of its poultry operation.
Remgro’s shareholding in Rainbow mirrored the shareholding that was held in RCL Foods at that time, being an interest of 80.2%.
In December 2025, Remgro diluted its effective interest in Maziv, held through CIVH, from 57% to approximately 40%, enabling Vodacom to acquire a 30% shareholding in Maziv. The transaction reunited Remgro with a long-standing partner in the telecommunications sector and introduced fresh capital and assets to support the continued growth of Maziv, South Africa’s market-leading fibre network operator.
In 2026, Remgro took a significant step in simplifying and focusing its healthcare portfolio by exchanging its 50% indirect exposure to Hirslanden, held through Mediclinic Group, for MSC’s 50% interest in Mediclinic Southern Africa. Following this milestone transaction, Remgro assumed 100% direct ownership of Mediclinic Southern Africa, while retaining a 50% interest in Mediclinic Holdings, which held the group’s interests in Mediclinic Middle East and Spire Healthcare in the United Kingdom.
During 2026, Remgro announced the final sell-down of its residual exposure to FirstRand, generating proceeds of R8 471 million. This transaction completed Remgro's divestment from FirstRand, a process that began with the unbundling of RMH in June 2020, and marked the substantial conclusion of a broader portfolio reduction process that had also included investments such as Momentum, BAT and Grindrod.
2026 © Remgro Limited
Ethics hotline 0800 222 536
